Alessandro Gronchi
Sarcoma surgeon who led the ISG-STS 1001 trial of histology-tailored neoadjuvant chemotherapy.
Alessandro Gronchi leads the sarcoma service at INT Milan and chaired ISG-STS 1001 and STRASS, trials that defined neoadjuvant chemotherapy and radiotherapy in high-risk soft-tissue sarcoma.
| Title | Journal | Year |
|---|---|---|
| Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001) | Lancet Oncology | 2017 |
Pages like this
not linked directly; found by shared links- TermHistotype-tailored therapy
Shares ISG-STS 1001, A same-week expert second opinion for every rare cancer diagnosis, Sarcomas (soft tissue, bone, GIST).
- PersonMarco Guzzo
Shares Fondazione IRCCS Istituto Nazionale dei Tumori, A same-week expert second opinion for every rare cancer diagnosis.
- TermFNCLCC grade (soft-tissue sarcoma)
- PersonJean-Yves Blay
Shares A same-week expert second opinion for every rare cancer diagnosis, Sarcomas (soft tissue, bone, GIST).
- ProductIfosfamide
- InstitutionSociety of Surgical Oncology
Shares European Society of Surgical Oncology, Sarcomas (soft tissue, bone, GIST).
- TechnologyHIPEC / PIPAC (intraperitoneal chemotherapy)
Shares Fondazione IRCCS Istituto Nazionale dei Tumori, European Society of Surgical Oncology.